UBS has upgraded AstraZeneca (NASDAQ:AZN) to buy from neutral, stating it believes the company's in-market growth potential has been underestimated. The investment bank said its forecasts for the ...

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...

Three new cancer treatments are to be made available on the NHS in Scotland, as six drugs are given the green light for use.